Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305016 · ClinicalTrials.gov registry record · Phase 3
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
A Phase 3 study, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 146
- Enrollment target
NCT03305016 is a Phase 3 study that has completed, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 146 participants.
The verdict
NCT03305016, a Phase 3 study, has completed, sponsored by Ascendis Pharma Endocrinology Division A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 146 participants
- Enrollment target
Study Summary
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.
Interventions
- DRUG TransCon hGH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2019-03-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03305016
The ClinicalTrials.gov registry entry for NCT03305016 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascendis Pharma Endocrinology Division A/S, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TransCon hGH is the first listed.
NCT03305016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03305016 about?
NCT03305016 is a clinical study titled "A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency". A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, b...
What is the current status of trial NCT03305016?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 146 participants. The study started on 2017-11-13. Estimated completion is 2019-03-19.
What interventions are being tested in trial NCT03305016?
The interventions under investigation include: TransCon hGH (DRUG).
Who is sponsoring clinical trial NCT03305016?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.